CRISPR Gene Therapy Shows 97% Success Rate in Long-Term Sickle Cell Trial
A CRISPR-based gene therapy continues showing remarkable results for patients with sickle cell disease, according to data published in the New England Journal of Medicine. Casgevy (exagamglogene autotemcel), the first FDA-approved therapy developed using CRISPR gene-editing technology, achieved ...
A CRISPR-based gene therapy continues showing remarkable results for patients with sickle cell disease, according to data published in the New England Journal of Medicine.
Casgevy (exagamglogene autotemcel), the first FDA-approved therapy developed using CRISPR gene-editing technology, achieved sustained benefit in more than 96% of patients treated in the CLIMB SCD-121 trial. According to results published in NEJM, 96.7% of patients (29 out of 30) were free from vaso-occlusive crises—the painful blockages that characterize sickle cell disease—for at least 12 consecutive months.
Longer-term follow-up data presented at the European Hematology Association congress in 2024 extended those findings. Among 39 evaluable patients with at least 16 months of follow-up, 92.3% remained crisis-free, with a mean duration of 27.9 months and some patients tracked for nearly five years.
"The increase in total hemoglobin is durable and approaches normal or near normal levels," said Franco Locatelli, MD, PhD, who presented the thalassemia data. "These longer follow-up data confirm that exa-cel provides a one-time functional cure."
The therapy works by editing patients' own hematopoietic stem cells to reactivate fetal hemoglobin production, which counteracts the defective adult hemoglobin that causes sickle cell. While patients still carry the genetic mutation, the treatment eliminates symptoms—hence the term "functional cure."
Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy received FDA approval in December 2023 for patients aged 12 and older with recurrent vaso-occlusive crises. The approval marked a watershed moment for CRISPR medicine, validating the technology's potential beyond rare genetic diseases.
Safety data showed no treatment-related malignancies, with side effects consistent with autologous stem cell transplant procedures.
For patients with sickle cell—a disease affecting approximately 100,000 Americans and causing chronic pain, organ damage, and shortened lifespans—the results represent a potential paradigm shift. The therapy requires a single treatment but involves chemotherapy conditioning and weeks of monitoring, making it a significant commitment with lasting benefit.
The findings add to growing evidence that CRISPR-based therapies can achieve durable clinical outcomes, following earlier successes in beta-thalassemia and ongoing research in other genetic conditions.
This article synthesizes peer-reviewed NEJM publication data with secondary coverage from Children's Hospital of Philadelphia and CGTlive, verified against the original clinical trial results. The story was produced through the full editorial pipeline: wire triage, beat reporting, fact-check, and editor review.
